 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. NASDAQ: TRIL to Pfizer Inc. for 18.50 per share in cash is fair to Trillium shareholders. Halper Sadeh encourages Trillium shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at 212 763-0060 or or The investigation concerns whether Tri 